MYEOV

Summary

MYEOV (myeloma overexpressed, HGNC:7563) is a protein-coding gene on chromosome 11q13.3, encoding Myeloma-overexpressed gene protein (Q96EZ4).

At a glance

• GWAS associations: 84
• Clinical variants (ClinVar): 6 total
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_001293291

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7563
Approved symbol	MYEOV
Name	myeloma overexpressed
Location	11q13.3
Locus type	gene with protein product
Status	Approved
Aliases	OCIM
Ensembl gene	ENSG00000172927
Ensembl biotype	protein_coding
OMIM	605625
Entrez	26579

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 6 protein_coding, 4 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000308946, ENST00000441339, ENST00000535407, ENST00000535597, ENST00000535653, ENST00000539691, ENST00000540760, ENST00000544008, ENST00000882027, ENST00000953492, ENST00000953493

RefSeq mRNA: 6 — MANE Select: NM_001293291 NM_001293291, NM_001293294, NM_001293296, NM_001300923, NM_001300924, NM_138768

CCDS: CCDS73340, CCDS8190

Canonical transcript exons

ENST00000441339 — 3 exons

Exon	Start	End
ENSE00001200273	69295592	69297287
ENSE00001423324	69294155	69294576
ENSE00002288234	69295233	69295495

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 97.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.7913 / max 545.9907, expressed in 1010 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115576	9.3323	534
115582	2.3176	603
115577	0.6082	190
115575	0.2093	85
115581	0.2046	98
115574	0.1194	58

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	97.17	gold quality
esophagus mucosa	UBERON:0002469	87.30	gold quality
esophagus squamous epithelium	UBERON:0006920	85.14	gold quality
buccal mucosa cell	CL:0002336	83.96	gold quality
pancreatic ductal cell	CL:0002079	83.78	silver quality
skin of leg	UBERON:0001511	83.14	gold quality
monocyte	CL:0000576	82.36	gold quality
leukocyte	CL:0000738	81.50	gold quality
skin of abdomen	UBERON:0001416	81.33	gold quality
zone of skin	UBERON:0000014	79.87	gold quality
subcutaneous adipose tissue	UBERON:0002190	78.27	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.16	gold quality
upper arm skin	UBERON:0004263	76.99	gold quality
amniotic fluid	UBERON:0000173	76.54	gold quality
vagina	UBERON:0000996	74.34	gold quality
mucosa of stomach	UBERON:0001199	73.28	gold quality
oral cavity	UBERON:0000167	71.77	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	71.10	gold quality
ileal mucosa	UBERON:0000331	70.92	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	70.70	gold quality
bone marrow cell	CL:0002092	70.24	gold quality
adipose tissue	UBERON:0001013	69.33	gold quality
thoracic mammary gland	UBERON:0005200	69.10	gold quality
mammary gland	UBERON:0001911	68.94	gold quality
esophagus	UBERON:0001043	68.26	gold quality
body of pancreas	UBERON:0001150	67.53	gold quality
nasal cavity mucosa	UBERON:0001826	67.52	gold quality
vermiform appendix	UBERON:0001154	67.35	gold quality
granulocyte	CL:0000094	66.91	gold quality
stromal cell of endometrium	CL:0002255	66.83	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-CURD-10	no	99.86
E-ANND-3	no	2.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting MYEOV, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-23A-5P	99.94	65.39	468
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-12122	99.56	69.33	1672
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-499A-3P	99.18	69.20	1392
HSA-MIR-499B-3P	99.18	69.27	1391
HSA-MIR-7109-5P	99.18	66.13	1057
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-670-3P	99.03	68.88	2404
HSA-MIR-6871-5P	98.90	66.67	671
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-3945	98.68	64.21	553
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6878-5P	98.49	67.91	2142

Literature-anchored findings (GeneRIF, showing 16)

• Epigenetic inactivation of myeov is associated with esophageal squamous cell carcinomas (PMID:12202983)
• MYEOV protein synthesis is regulated by upstream open reading frames (PMID:16275643)
• The putative role for MYEOV genes may provide important targets for intervention in Gastric adenocarcinoma, evidenced by their role in promoting invasion and proliferation, key phenotypic hallmarks of cancer cells. (PMID:16552434)
• These data suggest that ETV4 and Myeov may provide novel targets for therapeutic intervention. (PMID:16678123)
• Both myeov and hst (fgf4) are normally situated approximately 475-kb apart at band 11q13, a region that is frequently amplified and overexpressed in various tumours. (PMID:17390055)
• High MYEOV is associated with colon cancer cell migration. (PMID:20569498)
• MYEOV expression is a prognostic factor for patients with multiple myeloma, in part through a role of MYEOV in the control of MMC proliferation. (PMID:20854874)
• The results of these studies provide supporting evidence for MYEOV and NEGR1 as gene targets of 11q13 gains and 1p31 deletions in a neuroblastoma subset. (PMID:21624008)
• experiments demonstrated that the MYEOV ceRNA sequestered miR-30c-2-3p from binding its targets TGFBR2 and USP15 mRNAs, which in turn leading to constitutive activation of TGF-beta signaling and tumor progression in Non-small cell lung cancer. (PMID:30181549)
• Overexpression of MYEOV predicting poor prognosis in patients with pancreatic ductal adenocarcinoma. (PMID:32420813)
• MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity. (PMID:32879444)
• High expression of MYEOV reflects poor prognosis in non-small cell lung cancer. (PMID:33278551)
• The MYEOV-MYC association promotes oncogenic miR-17/93-5p expression in pancreatic ductal adenocarcinoma. (PMID:34930894)
• MYEOV overexpression induced by demethylation of its promoter contributes to pancreatic cancer progression via activation of the folate cycle/c-Myc/mTORC1 pathway. (PMID:36698109)
• MYEOV with High Frequencies of Mutations in Head and Neck Cancers Facilitates Cancer Cell Malignant Behaviors. (PMID:37667096)
• Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma. (PMID:38490328)

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

Myeloma-overexpressed gene protein — Q96EZ4 (reviewed: Q96EZ4)

Alternative names: Oncogene in multiple myeloma

All UniProt accessions (2): Q96EZ4, F5H0B3

UniProt curated annotations — full annotation on UniProt →

RefSeq proteins (6): NP_001280220, NP_001280223, NP_001280225, NP_001287852, NP_001287853, NP_620123 (=MANE)

Domains & families (InterPro)

UniProt features (7 total): sequence variant 4, chain 1, region of interest 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96EZ4-F1	30.94	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 61 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, chr11q13, NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_UP, CHEN_NEUROBLASTOMA_COPY_NUMBER_GAINS, VECCHI_GASTRIC_CANCER_EARLY_UP, DODD_NASOPHARYNGEAL_CARCINOMA_DN, VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_DN, WIERENGA_STAT5A_TARGETS_DN, BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP, BHAT_ESR1_TARGETS_VIA_AKT1_UP, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4, ANDERSEN_CHOLANGIOCARCINOMA_CLASS2, FORTSCHEGGER_PHF8_TARGETS_DN, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1

Protein interactions and networks

STRING

370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYEOV	CTTN	Q14247	792
MYEOV	CCND1	P24385	783
MYEOV	LTO1	Q8WV07	670
MYEOV	IGHV4-38-2	P0DP08	583
MYEOV	KLK3	P07288	561
MYEOV	TPCN2	Q8NHX9	478
MYEOV	CEP152	O94986	471
MYEOV	MRGPRF	Q96AM1	435
MYEOV	PPFIA1	Q13136	431
MYEOV	ANO1	Q5XXA6	400
MYEOV	FGF19	O95750	399
MYEOV	COPS9	Q8WXC6	397
MYEOV	ZNF486	Q96H40	388
MYEOV	LGALS16	A8MUM7	385
MYEOV	ZNF320	A2RRD8	382

IntAct

15 interactions, top by confidence:

A	B	Type	Score
MYEOV	CNN1	psi-mi:“MI:0914”(association)	0.560
DAZAP2	MYEOV	psi-mi:“MI:0915”(physical association)	0.560
TRIP13	MYEOV	psi-mi:“MI:0915”(physical association)	0.560
OPTN	MYEOV	psi-mi:“MI:0915”(physical association)	0.560
MYEOV	CNN1	psi-mi:“MI:0915”(physical association)	0.560
MYEOV	BAG6	psi-mi:“MI:0914”(association)	0.530
MYEOV	CFTR	psi-mi:“MI:0915”(physical association)	0.370
MYEOV	PYGM	psi-mi:“MI:0914”(association)	0.350
MYEOV	DAZAP2	psi-mi:“MI:0915”(physical association)	0.000
MYEOV	TRIP13	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): PRTFDC1 (Affinity Capture-MS), PRTFDC1 (Affinity Capture-MS), CNN1 (Affinity Capture-MS), MYEOV (Two-hybrid), DAZAP2 (Two-hybrid), MYEOV (Affinity Capture-RNA), CNN1 (Affinity Capture-MS), SUFU (Affinity Capture-MS), TUBB8 (Affinity Capture-MS), BAG6 (Affinity Capture-MS), PYGM (Affinity Capture-MS), PCK1 (Affinity Capture-MS), UBL4A (Affinity Capture-MS), PCBP3 (Affinity Capture-MS), UBQLN4 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GUT2, A2RUQ5, A8MU10, B1AH88, C0HM98, H3BQW9, P0C044, P0C092, P0CAT3, P0DPA3, P20977, P59052, P87743, Q06250, Q1R1V4, Q2M3A8, Q3SXR2, Q5SWW7, Q6Q795, Q6UXR6, Q6UXR8, Q6ZSR3, Q6ZSV7, Q6ZVH6, Q6ZWC4, Q71F78, Q86UQ8, Q8N2C9, Q8N2X6, Q8N616, Q8N814, Q8N8V8, Q8N9P6, Q8NBC4, Q8NBF4, Q96EZ4, Q96MC9, Q9BE57, Q9BR10, Q9BTD1

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — PRAD.

Clinical variants and AI predictions

ClinVar

6 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	4
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1987 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:69295745:T:C	F99L	0.963
11:69295747:T:A	F99L	0.963
11:69295747:T:G	F99L	0.963
11:69295628:T:C	F60L	0.955
11:69295630:C:A	F60L	0.955
11:69295630:C:G	F60L	0.955
11:69295730:T:C	F94L	0.953
11:69295732:T:A	F94L	0.953
11:69295732:T:G	F94L	0.953
11:69295955:T:C	F169L	0.949
11:69295957:T:A	F169L	0.949
11:69295957:T:G	F169L	0.949
11:69295649:T:C	F67L	0.936
11:69295651:C:A	F67L	0.936
11:69295651:C:G	F67L	0.936
11:69295472:T:C	F40L	0.928
11:69295474:C:A	F40L	0.928
11:69295474:C:G	F40L	0.928
11:69295481:T:C	F43L	0.839
11:69295483:C:A	F43L	0.839
11:69295483:C:G	F43L	0.839
11:69295629:T:C	F60S	0.829
11:69295746:T:C	F99S	0.814
11:69295746:T:G	F99C	0.799
11:69296038:G:C	W196C	0.788
11:69296038:G:T	W196C	0.788
11:69295956:T:C	F169S	0.755
11:69296031:T:C	I194T	0.746
11:69295629:T:G	F60C	0.737
11:69296230:G:C	W260C	0.730

dbSNP variants (sampled 300 via entrez): RS1001190566 (11:69293710 C>A), RS1001491443 (11:69293964 G>A), RS1001788493 (11:69292560 G>A,C), RS1001883178 (11:69293833 C>T), RS1002494255 (11:69295200 G>A), RS1002601604 (11:69294918 C>T), RS1002843147 (11:69292329 C>T), RS1002992382 (11:69297764 C>T), RS1003050287 (11:69294115 C>A), RS1003148975 (11:69292524 G>A), RS1003842469 (11:69294383 A>C,T), RS1004521674 (11:69294361 C>G,T), RS1004554509 (11:69294073 C>A), RS1005510777 (11:69295613 G>A), RS1006226204 (11:69292566 C>A,G,T)

Disease associations

OMIM: gene MIM:605625 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

84 associations (top):

Study	Trait	p-value
GCST000678_13	Breast cancer	3.000000e-15
GCST002413_9	Prostate cancer (early onset)	2.000000e-07
GCST002783_446	Body mass index	7.000000e-07
GCST002783_522	Body mass index	8.000000e-07
GCST002783_88	Body mass index	1.000000e-06
GCST002804_7	Antibody level in response to infection	6.000000e-07
GCST002890_9	Prostate cancer	2.000000e-13
GCST003586_5	Prostate cancer	1.000000e-11
GCST003985_11	Breast size	1.000000e-09
GCST004066_115	Hip circumference	4.000000e-08
GCST004066_42	Hip circumference	8.000000e-06
GCST004280_80	Diastolic blood pressure	2.000000e-12
GCST004904_88	Body mass index	4.000000e-09
GCST006976_22	Macular thickness	2.000000e-22
GCST007094_211	Diastolic blood pressure	2.000000e-09
GCST007272_29	Pulse pressure	1.000000e-31
GCST007354_9	Intracranial aneurysm	1.000000e-11
GCST008839_169	Height	6.000000e-12
GCST008839_207	Height	4.000000e-25
GCST008839_375	Height	2.000000e-08
GCST008867_6	Tyrosine levels	6.000000e-07
GCST009462_111	Optic disc size	6.000000e-09
GCST011829_5	Prostate cancer	3.000000e-08
GCST012229_145	Hip index	1.000000e-09
GCST012229_146	Hip index	4.000000e-11
GCST012229_147	Hip index	3.000000e-13
GCST012229_148	Hip index	8.000000e-17
GCST012229_149	Hip index	6.000000e-09
GCST012229_150	Hip index	2.000000e-08
GCST012229_151	Hip index	2.000000e-13

EFO canonical traits (12, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0007034	seropositivity measurement
EFO:0007036	herpes virus seropositivity
EFO:0006336	diastolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0005058	tyrosine measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density
EFO:0004980	appendicular lean mass
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression, decreases expression, decreases methylation	3
Arsenic	decreases methylation, affects cotreatment, increases abundance, increases expression, decreases expression	3
Vehicle Emissions	decreases expression, decreases reaction, increases abundance, increases expression	3
Particulate Matter	increases expression, decreases expression, decreases reaction, increases abundance	3
Air Pollutants	increases abundance, increases expression, decreases expression	2
Nickel	decreases expression	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
sulforaphane	increases expression	1
butyraldehyde	increases expression	1
tobacco tar	decreases reaction, decreases expression	1
manganese chloride	decreases expression, increases abundance	1
pentanal	increases expression	1
ICG 001	affects expression	1
abrine	increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	decreases reaction, decreases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
trametinib	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
MT19c compound	decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Temozolomide	increases expression	1
Decitabine	decreases expression, decreases reaction	1
Acetaminophen	decreases expression	1
Arsenicals	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.